Overall survival and long-term outcomes from the randomized, double-blind, placebocontrolled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes

Valeria Santini; Rami S. Komrokji; Michael R. Savona; María Díez-Campelo; Pierre Fenaux; Mikkael A. Sekeres; Yazan F. Madanat; David Valcárcel; Anna Jonasova; Petra Belohlavkova; Tymara Berry; Souria Dougherty; Sheetal Shah; Qi Xia; Libo Sun; Ying Wan; Fei Huang; Faye Feller; Shyamala Navada; Amer M. Zeidan; Uwe Platzbecker

doi:10.3324/haematol.2026.301456

Key Points

Evaluate overall survival and durable long-term efficacy outcomes of imetelstat treatment in patients diagnosed with lower-risk myelodysplastic syndromes.
Randomized, double-blind, placebo-controlled, phase III clinical study (IMerge trial).
Assessed imetelstat administration compared with placebo in patients with lower-risk myelodysplastic syndromes.
Assesses overall survival and extended clinical response outcomes in patients treated with imetelstat compared to placebo.
Specific numerical event rates, effect estimates (hazard ratios), confidence intervals, and p-values were omitted from the provided text.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized double-blind trial reports overall survival and long-term outcomes of imetelstat in lower-risk myelodysplastic syndromes, highlighting sustained clinical benefit.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Santini et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4046b95aff0620eb53f https://doi.org/10.3324/haematol.2026.301456

View Full Paper

Ask AI

Bookmark

Share

Overall survival and long-term outcomes from the randomized, double-blind, placebocontrolled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Overall survival and long-term outcomes from the randomized, double-blind, placebocontrolled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading